AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Study to Investigate Safety, Tolerability and Pharmacokinetics of AZD2423 Multiple Doses in Healthy Japanese Volunteers
- First Posted Date
- 2010-11-03
- Last Posted Date
- 2011-04-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 19
- Registration Number
- NCT01233830
- Locations
- 🇯🇵
Research Site, Fukuoka, Japan
Pulmicort Respules 0.25/0.5 Specific Clinical Experience Investigation
Completed
- Conditions
- Bronchial Asthma
- First Posted Date
- 2010-11-02
- Last Posted Date
- 2013-01-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 633
- Registration Number
- NCT01232322
Symbicort Turbuhaler 30/60 Specific Clinical Experience Investigation
Completed
- Conditions
- Bronchial Asthma
- First Posted Date
- 2010-11-02
- Last Posted Date
- 2013-05-29
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1500
- Registration Number
- NCT01232335
- Locations
- 🇯🇵
Research Site, Yamanashi, Japan
Symbicort Turbuhaler 30/60 Clinical Experience Investigation
Completed
- Conditions
- Bronchial Asthma
- First Posted Date
- 2010-11-02
- Last Posted Date
- 2011-12-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 3643
- Registration Number
- NCT01232348
- Locations
- 🇯🇵
Research Site, Yamanashi, Japan
Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules
Phase 1
Completed
- Conditions
- Advanced Solid MalignancyPharmacokineticsTumour ResponseSafety and TolerabilityAdvanced or Metastatic Breast CancerPTENER PositiveOvarian CancerPIK3CAAKT1
- Interventions
- First Posted Date
- 2010-10-22
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 285
- Registration Number
- NCT01226316
- Locations
- 🇬🇧
Research Site, Sutton, United Kingdom
Study to Assess the Effect of Ticagrelor on Coronary Blood Flow in Healthy Male Subjects.
Phase 1
Completed
- Conditions
- Blood Flow SpeedCoronary Flow Velocity
- Interventions
- Drug: Placebo
- First Posted Date
- 2010-10-22
- Last Posted Date
- 2012-02-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 39
- Registration Number
- NCT01226602
- Locations
- 🇸🇪
Research Site, Uppsala, Sweden
The Study Will Evaluate the Efficacy of AZD5423 in Patients With Mild Asthma Challenged With an Inhaled Allergen
Phase 2
Completed
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2010-10-21
- Last Posted Date
- 2015-04-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 27
- Registration Number
- NCT01225549
- Locations
- 🇨🇦
Research Site, Quebec, Canada
Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin
Phase 3
Completed
- Conditions
- Myocardial InfarctionAtherothrombosisStrokeCardiovascular Death
- Interventions
- First Posted Date
- 2010-10-21
- Last Posted Date
- 2016-01-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 21379
- Registration Number
- NCT01225562
- Locations
- 🇬🇧
Research Site, York, United Kingdom
A Study Conducted Over 3 Periods to Look at the Drug in the Body
- First Posted Date
- 2010-10-21
- Last Posted Date
- 2011-03-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 18
- Registration Number
- NCT01225939
- Locations
- 🇬🇧
Research Site, London Bridge, United Kingdom
Magnetic Marker Monitoring (MMM) Study With Gel Matrix Tablets Under Fasting and Fed Conditions
Phase 1
Completed
- Conditions
- Time for Colon ArrivalGastrointestinal-transportSmall Intestinal Transit TimeFood EffectMagnetic Marker MonitoringGastric Emptying Time
- Interventions
- Drug: D1000085Drug: D1000082Drug: D1000083Drug: D1000078
- First Posted Date
- 2010-10-20
- Last Posted Date
- 2010-11-04
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 5
- Registration Number
- NCT01224587
- Locations
- 🇩🇪
Research Site, Berlin, Germany